Studies blood samples to predict multiple myeloma in high-risk people
Collects blood samples from people with early myeloma precursor conditions to study risk factors.
Plain-language title generated from the registry record
Registry title: Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Dana-Farber Cancer InstituteBoston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dana-Farber Cancer Institute
- Trial code
- NCT03689595
- Record updated
- 31 July 2026
- Original description
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.Read full original descriptionShow less
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Inclusion: Age ≥ 30 years; AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer; OR; Those over 18 are also eligible if they have 2 or more family members with a blood cancer; Screened positive by mass spectrometry in the Ghobrial Lab for SMM or MGUS as part of the Mass General Brigham Biobank arm AND fits one of the following two groups of criteria:; Age ≥ 30 years; AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer; OR • Those over 18 are also eligible if they have 2 or more family members with a blood cancer; Screened positive by mass spectrometry in the Ghobrial Lab for SMM or MGUS as part of the Mass General Brigham Biobank arm AND fits the criteria listed below:; Age ≥ 18 years.
Exclusion: Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy; Persons under the age of 18 years old; First-degree relatives would not need to be identified by the participant; This study includes all special populations who fall within the eligible high-risk age range, ≥ 30 years of age, including adults unable to consent, pregnant women, and prisoners. These populations will not be excluded as this is a non-therapeutic study; Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia.